



# Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat

Corp Office : A/7, Sai Prasad, 2nd Floor, Teli Gali Cross Lane, Andheri (East), Mumbai - 400 069

(Rs. in Lakhs)

## Statement of Standalone Audited Results for the Quarter and for the Year Ended 31 MARCH, 2012

Particulars	Quarter Ended 31-Mar-12 (Unaudited)	Quarter Ended 31-Dec-11 (Unaudited)	Quarter Ended 31-Mar-11 (Unaudited)	Year ended 31-Mar-12 (Audited)	Year Ended 31-Mar-11 (Audited)
1 (a). Net Income from Sales / Services	1,559.31	1,800.15	1,061.70	6,954.31	4,342.95
(b). Other Operating Income	0.68	0.04	0.19	0.77	0.19
Total Income	1,559.99	1,800.19	1,061.89	6,955.08	4,343.14
2. Expenditure					
a) (Increase)/Decrease in Stock in Trade/WIP	18.22	(211.69)	118.44	(588.77)	(40.13)
b) Consumption of Raw Materials	1,562.56	1,873.70	780.11	6,497.48	3,773.79
c) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00
d) Employee Costs	23.39	20.37	16.23	79.88	50.58
e) Depreciation	5.59	4.60	4.11	19.28	16.13
f) Other Expenditure					
(i) Manufacturing Expenses	44.62	54.00	42.55	172.16	202.63
(ii) Administration Expenses	21.76	16.73	(7.08)	80.66	63.88
(iii) Selling & Distribution Expenses	25.48	31.67	26.77	77.20	51.63
g) Total	1,701.62	1,789.38	981.13	6,337.89	4,118.51
3. Profit from Operations before Other Income, Interest and Exceptional Items	(141.63)	10.81	80.76	617.19	224.63
4. Other Income	10.04	3.12	3.60	24.31	14.37
5. Profit before Interest and Exceptional items	(131.59)	13.93	84.36	641.50	239.00
6. Interest	14.07	10.98	4.63	61.60	27.92
7. Profit after Interest but before Exceptional items	(145.66)	2.95	79.73	579.90	211.08
8. Exceptional Items	0.00	0.00	0.00	0.00	0.00
9. Profit/(Loss) from ordinary activities before tax	(145.66)	2.95	79.73	579.90	211.08
10. Tax expense (incl deferred tax)	18.28	1.71	43.87	202.17	76.87
11 Net Profit/(Loss) from ordinary activities after tax	(163.94)	1.24	35.86	377.73	134.21
12. Extraordinary Items (Net of tax expense)	0.00	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period	(163.94)	1.24	35.86	377.73	134.21
14. Paid-up Equity Share Capital	308.97	308.97	308.97	308.97	308.97
15. Reserves excluding revaluation reserves	-	-	-	940.69	562.97
16. Earnings per share					
a) Basic and diluted EPS before extraordinary items for the period, year-to-date, previous year	(5.31)	0.04	1.16	12.23	4.34
b) Basic and diluted EPS after extraordinary items for the period, year-to-date, previous year	(5.31)	0.04	1.16	12.23	4.34
17. Public shareholding					
-- Number of shares	1,664,521	1,686,404	1,738,376	1,664,521	1,738,376
-- Percentage of shareholding	53.87	54.58	56.26	53.87	56.26
18. Promoters and promoter group shareholding**					
a) Pledged/ Encumbered					
-- Number of shares	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00
b) Non-encumbered					
-- Number of shares	1,425,179	1,403,296	1,351,324	1,425,179	1,351,324
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
-- Percentage of shares (as a % of the total share capital of the company)	46.13	45.42	43.74	46.13	43.74



# Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

## Standalone Statement of Assets and Liabilities

Particulars	Year to date ended 31-Mar-2012 (Audited)	Year to date ended 31-Mar-2011 (Audited)
<b><u>EQUITY AND LIABILITIES</u></b>		
<b>SHAREHOLDERS' FUNDS:</b>		
(a) Capital	308.97	308.97
(b) Reserves and Surplus	940.69	562.97
(c) Money Received Against Share Warrants	0.00	0.00
Sub total- Shareholders' Fund	1,249.66	871.94
<b>SHARE APPLICATION MONEY PENDING ALLOTMENT</b>	0.00	0.00
<b>NON - CURRENT LIABILITIES</b>		
(a) Long-Term Borrowings	132.02	0.00
(b) Deferred Tax Liabilities (Net)	25.02	23.20
(c) Other Long-Term Liabilities	0.00	0.00
(d) Long-Term Provisions	0.00	0.00
Sub total- Non Current Liabilities	157.04	23.20
<b>CURRENT LIABILITIES</b>		
(a) Short-Term Borrowings	210.06	163.24
(b) Trade Payables	1,385.53	792.80
(c) Other Current Liabilities	3.81	2.28
(d) Short-Term Provisions	145.46	25.94
Sub total- Current Liabilities	1,744.86	984.26
<b>Total - Equity and Liabilities</b>	<b>3,151.56</b>	<b>1,879.40</b>
<b><u>ASSETS</u></b>		
<b>NON-CURRENT ASSETS</b>		
(a) Fixed Assets	639.15	297.55
(b) Non-Current Investment	0.00	0.00
(c) Deferred Tax Assets (Net)	0.00	0.00
(d) Long-Term Loans And Advances	10.27	8.30
(e) Other Non-Current Assets	13.76	11.24
Sub total- Non Current Assets	663.18	317.09
<b>CURRENT ASSETS</b>		
(a) Current Investment	0.00	0.00
(b) Inventories	736.73	308.06
(c) Trade Receivables	1,050.13	937.01
(d) Cash And Cash Equivalents	444.87	149.61
(e) Short-term loans and advances	2.16	1.80
(f) Other current assets	254.49	165.83
Sub total- Current Assets	2,488.38	1,562.31
<b>Total - Assets</b>	<b>3,151.56</b>	<b>1,879.40</b>



# Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

**Notes:**

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The above results have been taken on record by the Board of Directors at its Meeting held on Wednesday, 30 May 2012 at the Corporate Office of the Company.
3. The above figures are after accounting for a net foreign exchange loss of Rs.144.27 lakhs during the year.
4. Information on investor complaints pursuant to clause 41 of the listing agreement for the quarter ended 31 March, 2012:

Opening Balance as on	1/Jan/2012	0
Received during the quarter		0
Disposed of during the quarter		0
Closing Balance as on	31/Mar/2012	0

5. The figures for the previous period have been regrouped where necessary to conform to current period's classification.

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Place : Mumbai**  
**Date : 30 May 2012**

**Lalit Mehta**  
**Managing Director**